Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Absence of sclerostin adversely affects B-cell survival.

Cain CJ, Rueda R, McLelland B, Collette NM, Loots GG, Manilay JO.

J Bone Miner Res. 2012 Jul;27(7):1451-61. doi: 10.1002/jbmr.1608.

2.

Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression.

Li C, Wang W, Xie L, Luo X, Cao X, Wan M.

Ann N Y Acad Sci. 2016 Jan;1364:62-73. doi: 10.1111/nyas.12750. Epub 2015 Apr 2.

3.

Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.

Tu X, Rhee Y, Condon KW, Bivi N, Allen MR, Dwyer D, Stolina M, Turner CH, Robling AG, Plotkin LI, Bellido T.

Bone. 2012 Jan;50(1):209-17. doi: 10.1016/j.bone.2011.10.025. Epub 2011 Oct 30.

4.

Mef2c deletion in osteocytes results in increased bone mass.

Kramer I, Baertschi S, Halleux C, Keller H, Kneissel M.

J Bone Miner Res. 2012 Feb;27(2):360-73. doi: 10.1002/jbmr.1492.

5.

Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium.

Ryan ZC, Ketha H, McNulty MS, McGee-Lawrence M, Craig TA, Grande JP, Westendorf JJ, Singh RJ, Kumar R.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6199-204. doi: 10.1073/pnas.1221255110. Epub 2013 Mar 25.

6.

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.

Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C.

J Bone Miner Res. 2008 Jun;23(6):860-9. doi: 10.1359/jbmr.080216.

7.

p190-B RhoGAP regulates the functional composition of the mesenchymal microenvironment.

Raman R, Kumar RS, Hinge A, Kumar S, Nayak R, Xu J, Szczur K, Cancelas JA, Filippi MD.

Leukemia. 2013 Nov;27(11):2209-19. doi: 10.1038/leu.2013.103. Epub 2013 Apr 8.

8.

The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis.

Fairfield H, Falank C, Harris E, Demambro V, McDonald M, Pettitt JA, Mohanty ST, Croucher P, Kramer I, Kneissel M, Rosen CJ, Reagan MR.

J Cell Physiol. 2018 Feb;233(2):1156-1167. doi: 10.1002/jcp.25976. Epub 2017 Jun 6.

PMID:
28460416
9.

Alterations in vitamin D metabolite, parathyroid hormone and fibroblast growth factor-23 concentrations in sclerostin-deficient mice permit the maintenance of a high bone mass.

Ryan ZC, Craig TA, McGee-Lawrence M, Westendorf JJ, Kumar R.

J Steroid Biochem Mol Biol. 2015 Apr;148:225-31. doi: 10.1016/j.jsbmb.2014.11.021. Epub 2014 Nov 22. Review.

10.

Targeted deletion of Sost distal enhancer increases bone formation and bone mass.

Collette NM, Genetos DC, Economides AN, Xie L, Shahnazari M, Yao W, Lane NE, Harland RM, Loots GG.

Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14092-7. doi: 10.1073/pnas.1207188109. Epub 2012 Aug 10.

11.

Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.

Kedlaya R, Veera S, Horan DJ, Moss RE, Ayturk UM, Jacobsen CM, Bowen ME, Paszty C, Warman ML, Robling AG.

Sci Transl Med. 2013 Nov 13;5(211):211ra158. doi: 10.1126/scitranslmed.3006627.

12.

CCAAT/enhancer-binding protein β expressed by bone marrow mesenchymal stromal cells regulates early B-cell lymphopoiesis.

Yoshioka S, Miura Y, Yao H, Satake S, Hayashi Y, Tamura A, Hishita T, Ichinohe T, Hirai H, Takaor-Kondo A, Maekawa T.

Stem Cells. 2014 Mar;32(3):730-40. doi: 10.1002/stem.1555.

13.

The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro.

Spatz JM, Wein MN, Gooi JH, Qu Y, Garr JL, Liu S, Barry KJ, Uda Y, Lai F, Dedic C, Balcells-Camps M, Kronenberg HM, Babij P, Pajevic PD.

J Biol Chem. 2015 Jul 3;290(27):16744-58. doi: 10.1074/jbc.M114.628313. Epub 2015 May 7.

14.

Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.

Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL.

Endocrinology. 2005 Nov;146(11):4577-83. Epub 2005 Aug 4.

PMID:
16081646
15.

The systemic effects of sclerostin overexpression using ΦC31 integrase in mice.

Zhang D, Park BM, Kang M, Nam H, Kim EJ, Bae C, Lim SK.

Biochem Biophys Res Commun. 2016 Apr 8;472(3):471-6. doi: 10.1016/j.bbrc.2016.01.178. Epub 2016 Feb 1.

PMID:
26845353
16.

Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels.

Chang MK, Kramer I, Huber T, Kinzel B, Guth-Gundel S, Leupin O, Kneissel M.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):E5187-95. doi: 10.1073/pnas.1413828111. Epub 2014 Nov 17.

17.

HDAC5 controls MEF2C-driven sclerostin expression in osteocytes.

Wein MN, Spatz J, Nishimori S, Doench J, Root D, Babij P, Nagano K, Baron R, Brooks D, Bouxsein M, Pajevic PD, Kronenberg HM.

J Bone Miner Res. 2015 Mar;30(3):400-11. doi: 10.1002/jbmr.2381.

18.

Low-dose PTH increases osteoblast activity via decreased Mef2c/Sost in senescent osteopenic mice.

Saidak Z, Le Henaff C, Azzi S, Marty C, Marie PJ.

J Endocrinol. 2014 Oct;223(1):25-33. doi: 10.1530/JOE-14-0249. Epub 2014 Jul 23.

19.

Genetics of Sost/SOST in Sclerosteosis and van Buchem Disease Animal Models.

Sebastian A, Loots GG.

Metabolism. 2017 Oct 25. pii: S0026-0495(17)30279-2. doi: 10.1016/j.metabol.2017.10.005. [Epub ahead of print]

Supplemental Content

Support Center